Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pepinemab + Pembrolizumab in R/M HNSCC
NCT04815720Phase 2Completed
- Sponsor
- Vaccinex, Inc.
- Start
- Aug 2021
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pepinemab in head and neck squamous cell carcinoma (HNSCC), sponsored by Vaccinex, Inc. Primary endpoints: Treatment Emergent Adverse Events at 2 years, Recommended Phase 2 Dose at 2 years and 1 more. Started Aug 2021; status: completed.
02
Drugs
pepinemab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04815720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04815720.